Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab + ipilimumab for symptomatic brain metastases in metastatic melanoma
2015-003199-56Phase 2Terminated
- Sponsor
- University Medical Center Groningen
- Start
- Sep 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab and ipilimumab in melanoma, sponsored by University Medical Center Groningen. Primary endpoint: Best overall response rate in the brain. Started Sep 2015; status: terminated.
02
Drugs
nivolumabipilimumab
03
Conditions
melanoma
Beyond the preview
Go deeper on 2015-003199-56.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003199-56.